161 related articles for article (PubMed ID: 31562954)
21. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
22. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.
Awasthi R; Rathbone MJ; Hansbro PM; Bebawy M; Dua K
Drug Deliv Transl Res; 2018 Feb; 8(1):97-110. PubMed ID: 29185148
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.
Parodi F; Carosio R; Ragusa M; Di Pietro C; Maugeri M; Barbagallo D; Sallustio F; Allemanni G; Pistillo MP; Casciano I; Forlani A; Schena FP; Purrello M; Romani M; Banelli B
Biochim Biophys Acta; 2016 Dec; 1859(12):1502-1514. PubMed ID: 27751904
[TBL] [Abstract][Full Text] [Related]
25. Potential anti-neuroblastoma agents from Juniperus oblonga.
Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
[TBL] [Abstract][Full Text] [Related]
26. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
27. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
[TBL] [Abstract][Full Text] [Related]
28. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
Liu HJ; Li GL; Lei PC
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
[No Abstract] [Full Text] [Related]
29. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology.
Rodríguez-Nogales C; Noguera R; Couvreur P; Blanco-Prieto MJ
J Pharmacol Exp Ther; 2019 Sep; 370(3):625-635. PubMed ID: 30635473
[TBL] [Abstract][Full Text] [Related]
31. A combined experimental and computational study on peptide nucleic acid (PNA) analogues of tumor suppressive miRNA-34a.
Piacenti V; Langella E; Autiero I; Nolan JC; Piskareva O; Adamo MFA; Saviano M; Moccia M
Bioorg Chem; 2019 Oct; 91():103165. PubMed ID: 31419642
[TBL] [Abstract][Full Text] [Related]
32. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma.
Guo J; Dong Q; Fang Z; Chen X; Lu H; Wang K; Yin Y; Cai X; Zhao N; Chen J; Zen K; Zhang J; Zhang CY
Cancer Biol Ther; 2010 Mar; 9(6):446-52. PubMed ID: 20147780
[TBL] [Abstract][Full Text] [Related]
33. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
Chen Y; Stallings RL
Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF).
Meseguer S; Mudduluru G; Escamilla JM; Allgayer H; Barettino D
J Biol Chem; 2011 Feb; 286(6):4150-64. PubMed ID: 21118818
[TBL] [Abstract][Full Text] [Related]
35. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
36. Towards diagnostic application of non-coding RNAs in neuroblastoma.
Althoff K; Schulte JH; Schramm A
Expert Rev Mol Diagn; 2016 Dec; 16(12):1307-1313. PubMed ID: 27813435
[TBL] [Abstract][Full Text] [Related]
37. Regulatory network analysis of microRNAs and genes in neuroblastoma.
Wang L; Che XJ; Wang N; Li J; Zhu MH
Asian Pac J Cancer Prev; 2014; 15(18):7645-52. PubMed ID: 25292042
[TBL] [Abstract][Full Text] [Related]
38. miRNA nanotherapeutics for cancer.
Ganju A; Khan S; Hafeez BB; Behrman SW; Yallapu MM; Chauhan SC; Jaggi M
Drug Discov Today; 2017 Feb; 22(2):424-432. PubMed ID: 27815139
[TBL] [Abstract][Full Text] [Related]
39. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential.
Galardi A; Colletti M; Businaro P; Quintarelli C; Locatelli F; Di Giannatale A
Curr Med Chem; 2018 Feb; 25(5):584-600. PubMed ID: 28971761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
